dat.linde2005 | R Documentation |
Results from 26 studies on the effectiveness of Hypericum perforatum extracts (St. John's wort) for treating depression.
dat.linde2005
The data frame contains the following columns:
id | numeric | study number |
study | character | study author(s) |
year | numeric | publication year |
country | character | study location |
ni | numeric | total sample size |
major | numeric | sample restricted to patients who met criteria for major depression |
baseline | numeric | HRSD baseline score |
version | numeric | HRSD version (17 or 21 items) |
duration | numeric | study duration (in weeks) |
prep | character | Hypericum extract preparation |
dosage | numeric | dosage (in mg) |
response | numeric | definition of response (see ‘Details’) |
ai | numeric | number of responses in treatment group |
n1i | numeric | number of patients in treatment group |
ci | numeric | number of responses in placebo group |
n2i | numeric | number of patients in placebo group |
group | numeric | stratification variable used by the authors (see ‘Details’) |
The dataset includes the results from 26 double-blind placebo-controlled trials on the effectiveness of Hypericum perforatum extracts (St. John's wort) for treating depression (note that 2 studies did not provide sufficient response information).
Data were extracted from Table 1 and Figure 3 from Linde et al. (2005). For study duration, the assessment week (instead of the total study duration) was coded for Philipp et al. (1999) and Montgomery et al. (2000). For dosage, the midpoint was coded when a range of values was given.
The definition of what constitutes a response
differed across studies and is coded as follows:
HRSD score reduction of at least 50% or HRSD score after therapy <10,
HRSD reduction of at least 50%,
based on HRSD scale but exact definition not reported,
global patient assessment of efficacy,
at least ‘much improved’ on the Clinical Global Impression sub-scale for global improvement.
The group
variable corresponds to the variable used by Linde et al. (2005) to stratify their analyses and is coded as follows:
smaller trials restricted to major depression,
larger trials restricted to major depression,
smaller trials not restricted to major depression,
larger trials not restricted to major depression.
medicine, psychiatry, risk ratios
Wolfgang Viechtbauer, wvb@metafor-project.org, https://www.metafor-project.org
Linde, K., Berner, M., Egger, M., & Mulrow, C. (2005). St John's wort for depression: Meta-analysis of randomised controlled trials. British Journal of Psychiatry, 186(2), 99–107. https://doi.org/10.1192/bjp.186.2.99
Viechtbauer, W. (2007). Accounting for heterogeneity via random-effects models and moderator analyses in meta-analysis. Zeitschrift für Psychologie / Journal of Psychology, 215(2), 104–121. https://doi.org/10.1027/0044-3409.215.2.104
### copy data into 'dat' and examine data dat <- dat.linde2005 head(dat) ## Not run: ### load metafor package library(metafor) ### remove studies with no response information and study with no responses in either group dat <- dat[-c(5,6,26),] ### calculate log risk ratios and corresponding sampling variances dat <- escalc(measure="RR", ai=ai, ci=ci, n1i=n1i, n2i=n2i, data=dat) head(dat) ### meta-analysis of the log risk ratios using a random-effects model res <- rma(yi, vi, data=dat, method="DL") res ### mixed-effects meta-regression model with stratification variable res <- rma(yi, vi, mods = ~ factor(group) - 1, data=dat, method="DL") res ### predicted average risk ratio for each level of the stratification variable predict(res, newmods=diag(4), transf=exp, digits=2) ## End(Not run)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.